NM_000465.4(BARD1):c.926C>T (p.Thr309Ile) AND Hereditary cancer-predisposing syndrome

Germline classification:
Uncertain significance (1 submission)
Last evaluated:
Jan 21, 2021
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV002375268.3

Allele description [Variation Report for NM_000465.4(BARD1):c.926C>T (p.Thr309Ile)]

NM_000465.4(BARD1):c.926C>T (p.Thr309Ile)

Gene:
BARD1:BRCA1 associated RING domain 1 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
2q35
Genomic location:
Preferred name:
NM_000465.4(BARD1):c.926C>T (p.Thr309Ile)
HGVS:
  • NC_000002.12:g.214780948G>A
  • NG_012047.3:g.33764C>T
  • NM_000465.4:c.926C>TMANE SELECT
  • NM_001282543.2:c.869C>T
  • NM_001282545.2:c.215+16113C>T
  • NM_001282548.2:c.159-28393C>T
  • NM_001282549.2:c.364+11349C>T
  • NP_000456.2:p.Thr309Ile
  • NP_001269472.1:p.Thr290Ile
  • LRG_297t1:c.926C>T
  • LRG_297:g.33764C>T
  • LRG_297p1:p.Thr309Ile
  • NC_000002.11:g.215645672G>A
  • NG_012047.2:g.33757C>T
  • NM_000465.2:c.926C>T
  • NM_000465.3:c.926C>T
  • NM_000465.4:c.926C>T
  • NR_104212.2:n.891C>T
  • NR_104215.2:n.834C>T
Protein change:
T290I
Links:
dbSNP: rs1236791029
NCBI 1000 Genomes Browser:
rs1236791029
Molecular consequence:
  • NM_001282545.2:c.215+16113C>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001282548.2:c.159-28393C>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001282549.2:c.364+11349C>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_000465.4:c.926C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001282543.2:c.869C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NR_104212.2:n.891C>T - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_104215.2:n.834C>T - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002686850Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Uncertain significance
(Jan 21, 2021)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From Ambry Genetics, SCV002686850.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The p.T309I variant (also known as c.926C>T), located in coding exon 4 of the BARD1 gene, results from a C to T substitution at nucleotide position 926. The threonine at codon 309 is replaced by isoleucine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024